At 13.1% CAGR, Europe Bioproduction Market is Projected to be Worth US$ 14,789.80 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Europe bioproduction market was valued at US$ 5,515.06 million in 2022 and is expected to reach US$ 14,789.80 million by 2030, registering a CAGR of 13.1% from 2022 to 2030. Patent expiry of blockbuster biologics and increasing prevalence of chronic diseases are among the critical factors attributed to drive the Europe bioproduction market growth.

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table.

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the bioproduction market during the forecast period.

On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of Europe bioproduction market.

Based on product, the Europe bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 38.2% Europe bioproduction market share in 2022, amassing US$ 2,106.27 million. It is projected to garner US$ 5,293.82 million by 2030 to register 12.2% CAGR during 2022–2030.

In terms of application, the Europe bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 37.3% share of Europe bioproduction market in 2022, amassing US$ 2,056.56 million. It is anticipated to garner US$ 5,737.88 million by 2030 to expand at 13.7% CAGR during 2022–2030.

By equipment, the Europe bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.3% share of Europe bioproduction market in 2022, amassing US$ 2,166.92 million. It is projected to garner US$ 6,142.60 million by 2030 to expand at 13.9% CAGR from 2022 to 2030.

In terms of end user, the Europe bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 52.8% share of Europe bioproduction market in 2022, amassing US$ 2,910.54 million. It is projected to garner US$ 7,720.31 million by 2030 to expand at 13.0% CAGR from 2022 to 2030.

Based on country, the Europe bioproduction market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 27.0% share of Europe bioproduction market in 2022. It was assessed at US$ 1,486.31 million in 2022 and is likely to hit US$ 4,175.16 million by 2030, registering a CAGR of 13.8% during 2022–2030.

Key players operating in the Europe bioproduction market are Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc., among others.

• In March 2023, Lonza declared that its intended cGMP clinical and commercial drug product production line in Visp (CH) has been completed. Customers with a range of production demands for drug products, for both clinical and commercial supply, will be served by the new line. Modern liquid and lyophilized vial filling isolator line for multiple modalities that satisfies the GMP Annex 1 requirement for the manufacture of sterile products is part of this 1,200 square metre cGMP facility1. The line is already completely operating and has a cGMP license; in April 2023, the first client batches are scheduled to be filled.
• In October 2023, Lonza announced the expansion of a partnership for the commercial-scale filling of ADCs with a significant biopharmaceutical partner. At its Stein (CH) facility, Lonza is required under the agreement to build a specialized aseptic cGMP filling line on a commercial scale. The aseptic filling of highly potent ADCs and containment lyophilization will be made possible by the new dedicated filling line. The extra filling capabilities bolster Lonza's ability and adaptability to support the commercial and clinical supply of bioconjugates even more.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com